WO2002026217A3 - Composition for the transdermal delivery of fentanyl - Google Patents

Composition for the transdermal delivery of fentanyl Download PDF

Info

Publication number
WO2002026217A3
WO2002026217A3 PCT/US2001/031052 US0131052W WO0226217A3 WO 2002026217 A3 WO2002026217 A3 WO 2002026217A3 US 0131052 W US0131052 W US 0131052W WO 0226217 A3 WO0226217 A3 WO 0226217A3
Authority
WO
WIPO (PCT)
Prior art keywords
fentanyl
composition
transdermal delivery
drug delivery
transdermal drug
Prior art date
Application number
PCT/US2001/031052
Other languages
French (fr)
Other versions
WO2002026217A2 (en
Inventor
Adam S Cantor
Terrance W Ocheltree
Cynthia A Robles
Original Assignee
3M Innovative Properties Co
Adam S Cantor
Terrance W Ocheltree
Cynthia A Robles
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26930280&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2002026217(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EEP200300123A priority Critical patent/EE05391B1/en
Priority to AT01983925T priority patent/ATE449599T1/en
Priority to DE60140616T priority patent/DE60140616D1/en
Priority to JP2002530047A priority patent/JP2004513890A/en
Priority to CA002423836A priority patent/CA2423836C/en
Priority to BR0114315-8A priority patent/BR0114315A/en
Priority to AU1531502A priority patent/AU1531502A/en
Application filed by 3M Innovative Properties Co, Adam S Cantor, Terrance W Ocheltree, Cynthia A Robles filed Critical 3M Innovative Properties Co
Priority to HU0302926A priority patent/HUP0302926A3/en
Priority to MXPA03002548A priority patent/MXPA03002548A/en
Priority to IL15485701A priority patent/IL154857A0/en
Priority to KR10-2003-7004485A priority patent/KR20030043978A/en
Priority to NZ524767A priority patent/NZ524767A/en
Priority to EP01983925A priority patent/EP1322299B1/en
Priority to AU2002215315A priority patent/AU2002215315C1/en
Publication of WO2002026217A2 publication Critical patent/WO2002026217A2/en
Publication of WO2002026217A3 publication Critical patent/WO2002026217A3/en
Priority to NO20031165A priority patent/NO333525B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl.
PCT/US2001/031052 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl WO2002026217A2 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
HU0302926A HUP0302926A3 (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
MXPA03002548A MXPA03002548A (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl.
AT01983925T ATE449599T1 (en) 2000-09-29 2001-09-27 COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF FENTANYL
IL15485701A IL154857A0 (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
CA002423836A CA2423836C (en) 2000-09-29 2001-09-27 Composition for the delivery of fentanyl
BR0114315-8A BR0114315A (en) 2000-09-29 2001-09-27 Transdermal fentanyl release composition
AU1531502A AU1531502A (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
EEP200300123A EE05391B1 (en) 2000-09-29 2001-09-27 A composition and means for transdermal administration thereof
AU2002215315A AU2002215315C1 (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
DE60140616T DE60140616D1 (en) 2000-09-29 2001-09-27 COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF FENTANYL
JP2002530047A JP2004513890A (en) 2000-09-29 2001-09-27 Compositions for transdermal delivery of fentanyl
KR10-2003-7004485A KR20030043978A (en) 2000-09-29 2001-09-27 Composition for the Transdermal Delivery of Fentanyl
NZ524767A NZ524767A (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
EP01983925A EP1322299B1 (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl
NO20031165A NO333525B1 (en) 2000-09-29 2003-03-13 Preparation for transdermal delivery of fentanyl

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23697300P 2000-09-29 2000-09-29
US60/236,973 2000-09-29
US28401701P 2001-04-16 2001-04-16
US60/284,017 2001-04-16

Publications (2)

Publication Number Publication Date
WO2002026217A2 WO2002026217A2 (en) 2002-04-04
WO2002026217A3 true WO2002026217A3 (en) 2002-10-31

Family

ID=26930280

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031052 WO2002026217A2 (en) 2000-09-29 2001-09-27 Composition for the transdermal delivery of fentanyl

Country Status (24)

Country Link
US (18) US20020119187A1 (en)
EP (6) EP2153827A3 (en)
JP (6) JP2004513890A (en)
KR (1) KR20030043978A (en)
CN (1) CN100490805C (en)
AR (1) AR037081A1 (en)
AT (1) ATE449599T1 (en)
AU (2) AU2002215315C1 (en)
BR (1) BR0114315A (en)
CA (1) CA2423836C (en)
CY (1) CY1118798T1 (en)
CZ (1) CZ305119B6 (en)
DE (1) DE60140616D1 (en)
DK (2) DK2153828T3 (en)
EE (1) EE05391B1 (en)
ES (2) ES2407987T3 (en)
HU (1) HUP0302926A3 (en)
IL (1) IL154857A0 (en)
MX (1) MXPA03002548A (en)
NO (1) NO333525B1 (en)
NZ (1) NZ524767A (en)
PL (1) PL360708A1 (en)
PT (2) PT2153828T (en)
WO (1) WO2002026217A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205090B2 (en) 2005-09-23 2015-12-08 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19814084B4 (en) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2 agonist-containing transdermal therapeutic system for the treatment of Parkinson's syndrome and process for its preparation
KR100940245B1 (en) * 2000-09-19 2010-02-04 내쇼날 스타치 앤드 케미칼 인베스트멘트 홀딩 코포레이션 Non-reactive adhesive useful in transdermal drug delivery systems
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
CZ307857B6 (en) * 2001-03-16 2019-07-03 Alza Corporation A transdermal patch for administering fentanyl or an analogue of it
DE20221397U1 (en) * 2001-03-16 2005-10-20 Alza Corp., Mountain View Transdermal patch, useful for administering fentanyl or its analog through the skin, comprises a backing layer on which a reservoir containing a single phase polymeric composition is disposed
US20050208117A1 (en) * 2001-03-16 2005-09-22 Venkatraman Subramanian S Transdermal administration of fentanyl and analogs thereof
AU2007202273B2 (en) * 2001-08-24 2009-11-05 Lts Lohmann Therapie - Systeme Ag Transdermal therapeutic system containing fentanyl or related substance
DE10141650C1 (en) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
AR039336A1 (en) * 2002-04-23 2005-02-16 Alza Corp TRANSDERMAL ANALGESIC SYSTEMS WITH REDUCED ABUSE POTENTIAL
AR033748A1 (en) 2002-05-15 2004-01-07 Thalas Group Inc A DEVICE FOR THE TRANSDERMAL ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE SUBSTANCES THAT INCLUDES TWO SUPERPOSED ADHESIVE LAYERS AND A PROCEDURE TO PREPARE IT
DE10223835A1 (en) * 2002-05-28 2003-12-11 Labtec Gmbh Transdermal therapeutic system for delivery of fentanyl, to treat severe and/or chronic pain, including drug-containing adhesive matrix of specific basic acrylate copolymer requiring no penetration accelerators
US20060039960A1 (en) * 2002-05-28 2006-02-23 Cordes Guenter Plaster containing fentanyl
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
DE10234673B4 (en) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Hot-melt TTS for the administration of rotigotine and process for its preparation, and use of rotigotine in the manufacture of a hot-melt TTS
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US20040086551A1 (en) * 2002-10-30 2004-05-06 Miller Kenneth J. Fentanyl suspension-based silicone adhesive formulations and devices for transdermal delivery of fentanyl
DE60204229T2 (en) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Administration of rotigotine for the treatment of Parkinson's disease by iontophoresis
DE10261696A1 (en) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Device for the transdermal administration of rotigotine base
US7182955B2 (en) * 2003-04-30 2007-02-27 3M Innovative Properties Company Abuse-resistant transdermal dosage form
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US20040219195A1 (en) * 2003-04-30 2004-11-04 3M Innovative Properties Company Abuse-resistant transdermal dosage form
CL2004000927A1 (en) 2003-04-30 2005-01-28 Purdue Pharma Lp TRANSDERMAL DOSAGE FORM THAT INCLUDES AN ACTIVE AGENT, A NEXT SURFACE AND A DISTAL SURFACE.
JP2007511605A (en) * 2003-11-18 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー Olanzapine-containing transdermal drug delivery composition
US20050202073A1 (en) 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
JP2007532645A (en) * 2004-04-13 2007-11-15 アルザ コーポレイション Devices and methods for transdermal delivery systems of drugs based on fentanyl
JP2008510713A (en) * 2004-08-20 2008-04-10 スリーエム イノベイティブ プロパティズ カンパニー Transdermal drug delivery device with translucent protective film
US8252319B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
US8608889B2 (en) * 2005-06-10 2013-12-17 3M Innovative Properties Company Method for handling adhesive laminate sections
EP1937226A2 (en) * 2005-09-23 2008-07-02 Alza Corporation Transdermal galantamine delivery system
US9056061B2 (en) * 2005-09-23 2015-06-16 Alza Corporation Transdermal nicotine salt delivery system
JP5114042B2 (en) * 2005-10-19 2013-01-09 ニプロパッチ株式会社 Patch and method for producing the patch
US7888422B2 (en) 2005-11-09 2011-02-15 Mylan Technologies Inc. Long-wearing removable pressure sensitive adhesive
GB0615136D0 (en) * 2006-07-29 2006-09-06 Univ Edinburgh Induction of analgesia in neuropathic pain
JP5227041B2 (en) * 2007-02-28 2013-07-03 日東電工株式会社 Drug-containing patch preparation
CN100465201C (en) * 2007-04-25 2009-03-04 上海大学 Method for preparing water-soluble resin latex in acrylic acid series in use for intestine soluble coating material for medication
US9017301B2 (en) * 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
WO2009052204A1 (en) * 2007-10-15 2009-04-23 Alza Corporation Once-a-day replacement transdermal administration of fentanyl
JP5431969B2 (en) 2008-01-28 2014-03-05 帝國製薬株式会社 Fentanyl-containing external patch
KR20090101579A (en) * 2008-03-24 2009-09-29 조선대학교산학협력단 Transdermal drug delivery system containing fentanyl
DE102009052972A1 (en) 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Process for preventing the crystallization of drugs in a polymer film
US9375510B2 (en) * 2010-07-21 2016-06-28 3M Innovative Properties Company Transdermal adhesive compositions, devices and methods
CN103930098B (en) * 2011-09-22 2017-06-06 株式会社三养生物制药 Transdermal formulation containing fentanyl and its homolog
EP2782584B1 (en) 2011-11-23 2021-06-09 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP2712612B1 (en) * 2012-09-28 2020-03-25 Nitto Denko Corporation Patch preparation containing amine oxide and isopropyl myristate
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (en) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． Natural combination hormone replacement therapy and therapy
RU2700032C2 (en) * 2014-08-25 2019-09-12 ХЕНКЕЛЬ АйПи ЭНД ХОЛДИНГ ГМБХ Acrylic polymers and use thereof in transdermal drug delivery
WO2016100708A1 (en) 2014-12-19 2016-06-23 3M Innovative Properties Company Transdermal drug delivery device including fentanyl
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CA2998439A1 (en) * 2015-09-18 2017-03-23 SlantRange, Inc. Systems and methods for determining statistics of plant populations based on overhead optical measurements
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
JP6500982B2 (en) * 2016-05-19 2019-04-17 三菱ケミカル株式会社 Macromonomer copolymer and method for producing the same
JPWO2019022249A1 (en) * 2017-07-28 2020-07-09 国立大学法人九州大学 Transdermal composition with controlled release of minoxidil
US20200297654A1 (en) 2017-10-17 2020-09-24 Lubrizol Advanced Materials, Inc. Composition and device for delivery of active agents to skin surfaces
CA3095873A1 (en) * 2018-04-05 2019-10-10 Steven Robert ERBST Therapeutic elastic bandage for modulating the endocannabinoid system
WO2020009685A1 (en) 2018-07-02 2020-01-09 John Tang Transdermal dosage form
WO2020008366A1 (en) 2018-07-02 2020-01-09 Clexio Biosciences Ltd. Transdermal dosage form
DE102019120403A1 (en) 2019-07-29 2021-02-04 Lts Lohmann Therapie-Systeme Ag Process for the production of pressure-sensitive adhesives for use in a transdermal therapeutic system
CN111471126A (en) * 2020-03-23 2020-07-31 杭州鹿扬科技有限公司 Adhesive material for skin and method for producing the same
US11877848B2 (en) 2021-11-08 2024-01-23 Satio, Inc. Dermal patch for collecting a physiological sample

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008229A2 (en) * 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery

Family Cites Families (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA677797A (en) 1955-11-18 1964-01-14 Minnesota Mining And Manufacturing Company Sheet material having a pressure-sensitive adhesive coating of acrylate ester copolymer
US3352708A (en) * 1964-03-02 1967-11-14 Ball Brothers Co Inc Glass having dual protective coatings thereon and method for forming such coatings
US3886126A (en) * 1973-04-09 1975-05-27 Monsanto Co Solutions of pressure-sensitive resin solutions with improved viscosity and flow
US3900610A (en) * 1973-04-09 1975-08-19 Monsanto Co Process of making a pressure sensitive adhesive article
US4405616A (en) * 1975-06-19 1983-09-20 Nelson Research & Development Company Penetration enhancers for transdermal drug delivery of systemic agents
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator
US4314557A (en) * 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4379454A (en) * 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4460372A (en) * 1981-02-17 1984-07-17 Alza Corporation Percutaneous absorption enhancer dispenser for use in coadministering drug and percutaneous absorption enhancer
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
US5310559A (en) * 1982-09-01 1994-05-10 Hercon Laboratories Corporation Device for controlled release and delivery to mammalian tissue of pharmacologically active agents incorporating a rate controlling member which comprises an alkylene-alkyl acrylate copolymer
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4568343A (en) * 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4693776A (en) 1985-05-16 1987-09-15 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive
US4698062A (en) * 1985-10-30 1987-10-06 Alza Corporation Medical device for pulsatile transdermal delivery of biologically active agents
US4732808A (en) 1985-11-14 1988-03-22 Minnesota Mining And Manufacturing Company Macromer reinforced pressure sensitive skin adhesive sheet material
US4954343A (en) * 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
US5820876A (en) * 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US4938759A (en) * 1986-09-02 1990-07-03 Alza Corporation Transdermal delivery device having a rate controlling adhesive
US4908027A (en) * 1986-09-12 1990-03-13 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US5344656A (en) * 1986-09-12 1994-09-06 Alza Corporation Subsaturated transdermal therapeutic system having improved release characteristics
US4917676A (en) * 1986-11-20 1990-04-17 Ciba-Geigy Corporation User-activated transdermal therapeutic system
US5006342A (en) * 1986-12-22 1991-04-09 Cygnus Corporation Resilient transdermal drug delivery device
AU607172B2 (en) * 1986-12-22 1991-02-28 Cygnus, Inc. Diffusion matrix for transdermal drug administration
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
AU601528B2 (en) * 1986-12-22 1990-09-13 Ortho-Mcneil Pharmaceutical, Inc. Resilient transdermal drug-delivery device and compositions and devices employing fatty acid esters/ethers of alkanediols and percutaneous absorption enhancers
US4876249A (en) * 1987-01-12 1989-10-24 Rajadhyaksha Vithal J Compositions and method comprising heterocyclic compounds containing two heteroatoms
US4911707A (en) * 1987-02-13 1990-03-27 Ciba-Geigy Corporation Monolithic user-activated transdermal therapeutic system
US4822802A (en) * 1987-02-24 1989-04-18 Alza Corporation Method of fentanly administration for postoperative pain relief
US4865848A (en) * 1987-02-26 1989-09-12 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US4900555A (en) * 1987-02-26 1990-02-13 Alza Corporation Skin permeation enhancer compositions using sucrose esters
US5186939A (en) * 1987-04-23 1993-02-16 Cygnus Therapeutic Systems Laminated composite for transdermal administration of fentanyl
US4879297A (en) * 1987-06-01 1989-11-07 Warner-Lambert Company Fatty acids and their small chain esters as penetration enhancers in aqueous systems
DE3729299A1 (en) * 1987-09-02 1989-03-23 Beiersdorf Ag TRANSDERMAL THERAPEUTIC SYSTEM
US4781924A (en) * 1987-11-09 1988-11-01 Alza Corporation Transdermal drug delivery device
US4837027A (en) * 1987-11-09 1989-06-06 Alza Corporation Transdermal drug delivery device
GB8804164D0 (en) * 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5300291A (en) * 1988-03-04 1994-04-05 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US5656286A (en) * 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US4994267A (en) 1988-03-04 1991-02-19 Noven Pharmaceuticals, Inc. Transdermal acrylic multipolymer drug delivery system
US5364630A (en) * 1988-06-14 1994-11-15 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5004610A (en) * 1988-06-14 1991-04-02 Alza Corporation Subsaturated nicotine transdermal therapeutic system
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
US5223262A (en) * 1989-02-23 1993-06-29 University Of Utah Transdermal delivery system utilizing one way membranes
US5162315A (en) * 1989-05-08 1992-11-10 Rajadhyaksha Vithal J Penetration enhancers
JP2718433B2 (en) * 1989-09-08 1998-02-25 シグナス インコーポレイテッド Solid matrix system for transdermal drug delivery
JP3046346B2 (en) * 1990-03-12 2000-05-29 昭和電工株式会社 External preparation base or auxiliary agent and human or animal external preparation containing it
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5152997A (en) * 1990-12-11 1992-10-06 Theratech, Inc. Method and device for transdermally administering testosterone across nonscrotal skin at therapeutically effective levels
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5352456A (en) * 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
US5239714A (en) * 1992-08-12 1993-08-31 Huang Ming T Playpen structure
JPH0679002A (en) * 1993-12-14 1994-03-22 Hisamitsu Pharmaceut Co Inc Patch device for percutaneous administration
DE4310012A1 (en) * 1993-03-27 1994-09-29 Roehm Gmbh Dermal therapeutic system made of a meltable poly (meth) acrylate mixture
ES2115231T3 (en) * 1993-04-20 1998-06-16 Hexal Ag PLASTER WITH ACTIVE SUBSTANCES.
US5762952A (en) * 1993-04-27 1998-06-09 Hercon Laboratories Corporation Transdermal delivery of active drugs
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US5554381A (en) * 1993-08-09 1996-09-10 Cygnus, Inc. Low flux matrix system for delivering potent drugs transdermally
JP3792252B2 (en) * 1993-09-29 2006-07-05 アルザ・コーポレーション Monoglyceride / lactate ester permeation enhancer for oxybutynin
US5714162A (en) * 1994-09-16 1998-02-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Scopolamine patch
US5635203A (en) * 1994-09-29 1997-06-03 Alza Corporation Transdermal device having decreased delamination
US5505958A (en) * 1994-10-31 1996-04-09 Algos Pharmaceutical Corporation Transdermal drug delivery device and method for its manufacture
CA2208132A1 (en) * 1994-12-21 1996-06-27 Theratech, Inc. Transdermal delivery system with adhesive overlay and peel seal disc
US5614210A (en) * 1995-03-31 1997-03-25 Minnesota Mining And Manufacturing Company Transdermal device for the delivery of alfuzosin
US5882676A (en) * 1995-05-26 1999-03-16 Alza Corporation Skin permeation enhancer compositions using acyl lactylates
US5693335A (en) * 1995-06-07 1997-12-02 Cygnus, Inc. Skin permeation enhancer composition for use with sex steroids
US6093419A (en) * 1995-06-07 2000-07-25 Lectec Corporation Compliance verification method and device in compulsory drug administration
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
DE19527925C2 (en) * 1995-07-29 1997-07-03 Lohmann Therapie Syst Lts Transdermal therapeutic system with a release agent-coated protective layer
US5900198A (en) * 1996-01-31 1999-05-04 Hori; Yasunori Method of producing molded resin product
JP3836566B2 (en) * 1996-05-13 2006-10-25 久光製薬株式会社 Fentanyl-containing transdermal administration tape formulation
TW411277B (en) * 1996-05-13 2000-11-11 Hisamitsu Pharmaceutical Co Percutaneous tape preparation containing fentanyl
US5985317A (en) * 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
CA2264687C (en) * 1996-10-24 2006-04-25 Alza Corporation Permeation enhancers for transdermal drug delivery compositions, devices, and methods
IT1286768B1 (en) 1996-11-15 1998-07-17 Alfredo Cecchini SWIVEL SUN BED
US5998911A (en) * 1996-11-26 1999-12-07 Ngk Insulators, Ltd. Vibrator, vibratory gyroscope, and vibration adjusting method
DE19653605C2 (en) * 1996-12-20 2002-11-28 Roehm Gmbh Adhesives and binders for dermal or transdermal therapy systems and their use for producing a transdermal therapy system
DE19653606A1 (en) * 1996-12-20 1998-06-25 Roehm Gmbh Adhesive and binder made from (meth) acrylate polymer, organic acid and plasticizer
US6203817B1 (en) * 1997-02-19 2001-03-20 Alza Corporation Reduction of skin reactions caused by transdermal drug delivery
ATE293960T1 (en) * 1997-02-28 2005-05-15 Minnesota Mining & Mfg TRANSDERMAL DEVICE FOR ADMINISTRATION OF TESTOSTERONE
US7150881B2 (en) 1997-06-26 2006-12-19 Mylan Technologies, Inc. Adhesive mixture for transdermal delivery of highly plasticizing drugs
GB9714650D0 (en) 1997-07-11 1997-09-17 Strakan Ltd Block copolymer
US5948433A (en) * 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
IT1294748B1 (en) * 1997-09-17 1999-04-12 Permatec Tech Ag FORMULATION FOR A TRANSDERMAL DEVICE
US6210705B1 (en) * 1997-12-15 2001-04-03 Noven Pharmaceuticals, Nc. Compositions and methods for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate
MXPA01001752A (en) * 1998-08-20 2002-04-08 3M Innovative Properties Co Spray on bandage and drug delivery system.
EP1061900B2 (en) 1999-01-14 2008-07-09 Noven Pharmaceuticals, Inc. Dermal compositions
CA2369012A1 (en) * 1999-04-13 2000-10-19 Hisamitsu Pharmaceutical Co., Inc. Preparations for percutaneous absorption
KR20010036685A (en) * 1999-10-11 2001-05-07 김윤 Transdermal fentanyl delivery matrix system
US6164190A (en) * 1999-12-16 2000-12-26 Tien Lin; Yu Mei Tea infusing device
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
CZ307857B6 (en) * 2001-03-16 2019-07-03 Alza Corporation A transdermal patch for administering fentanyl or an analogue of it
DE10141650C1 (en) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Safe transdermal therapeutic system for administration of fentanyl or analogous analgesics, having matrix layer of carboxy group-free polyacrylate adhesive providing high permeation rate
WO2003074035A1 (en) * 2002-03-06 2003-09-12 Hexal Ag Transdermal system comprising fentanyl
AR039336A1 (en) * 2002-04-23 2005-02-16 Alza Corp TRANSDERMAL ANALGESIC SYSTEMS WITH REDUCED ABUSE POTENTIAL
TWI296531B (en) * 2002-10-18 2008-05-11 Hisamitsu Pharmaceutical Co Transdermal adhesive preparations for topical administration of fentanyl
DE10252725A1 (en) * 2002-11-13 2004-06-03 Lts Lohmann Therapie-Systeme Ag Moisture-activated adhesives for medical applications
JP2007527415A (en) * 2003-10-30 2007-09-27 アルザ・コーポレーシヨン Transdermal analgesic system with low potential for abuse
JP4745747B2 (en) * 2004-08-12 2011-08-10 日東電工株式会社 Fentanyl-containing patch preparation
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996008229A2 (en) * 1994-09-14 1996-03-21 Minnesota Mining And Manufacturing Company Matrix for transdermal drug delivery

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROY S D ET AL: "CONTROLLED TRANSDERMAL DELIVERY OF FENTANYL: CHARACTERIZATIONS OF PRESSURE-SENSITIVE ADHESIVES FOR MATRIX PATCH DESIGN", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, VOL. 85, NR. 5, PAGE(S) 491-495, ISSN: 0022-3549, XP000583527 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205090B2 (en) 2005-09-23 2015-12-08 Alza Corporation High enhancer-loading polyacrylate formulation for transdermal applications
US9446004B2 (en) 2005-09-23 2016-09-20 Alza Corporation Transdermal nicotine salt delivery system

Also Published As

Publication number Publication date
EP1322299B1 (en) 2009-11-25
CA2423836A1 (en) 2002-04-04
CZ2003890A3 (en) 2003-09-17
AU2002215315B2 (en) 2007-05-10
KR20030043978A (en) 2003-06-02
JP4976445B2 (en) 2012-07-18
CN100490805C (en) 2009-05-27
US20110038918A1 (en) 2011-02-17
DK2158905T3 (en) 2013-05-27
NO20031165D0 (en) 2003-03-13
WO2002026217A2 (en) 2002-04-04
US20200000739A1 (en) 2020-01-02
US20190167603A1 (en) 2019-06-06
NZ524767A (en) 2004-12-24
EP1322299A2 (en) 2003-07-02
HUP0302926A3 (en) 2006-07-28
EE200300123A (en) 2005-04-15
US20170296486A1 (en) 2017-10-19
DK2153828T3 (en) 2017-04-10
NO333525B1 (en) 2013-07-01
JP5425751B2 (en) 2014-02-26
US20130295158A1 (en) 2013-11-07
US20160184235A1 (en) 2016-06-30
US20150313851A1 (en) 2015-11-05
BR0114315A (en) 2003-10-14
JP2013256536A (en) 2013-12-26
IL154857A0 (en) 2003-10-31
US20120034292A1 (en) 2012-02-09
AU2002215315C1 (en) 2010-09-02
EP2153827A2 (en) 2010-02-17
NO20031165L (en) 2003-05-26
US20120269878A2 (en) 2012-10-25
DE60140616D1 (en) 2010-01-07
US20170035704A1 (en) 2017-02-09
JP2009185061A (en) 2009-08-20
CZ305119B6 (en) 2015-05-13
CY1118798T1 (en) 2018-01-10
JP2016053083A (en) 2016-04-14
CA2423836C (en) 2009-11-24
PT2153828T (en) 2017-03-31
US20130064877A1 (en) 2013-03-14
EP2266547A1 (en) 2010-12-29
JP2004513890A (en) 2004-05-13
JP2010100650A (en) 2010-05-06
US20100255073A1 (en) 2010-10-07
EP2158905A3 (en) 2010-03-10
US20140170206A1 (en) 2014-06-19
US20220008352A1 (en) 2022-01-13
PT2158905E (en) 2013-05-22
US20180153823A1 (en) 2018-06-07
EP2153828A3 (en) 2010-03-10
US20060222691A1 (en) 2006-10-05
ES2621169T3 (en) 2017-07-03
ATE449599T1 (en) 2009-12-15
US20150025480A1 (en) 2015-01-22
EP2158905A2 (en) 2010-03-03
AR037081A1 (en) 2004-10-20
EE05391B1 (en) 2011-04-15
US20200253887A1 (en) 2020-08-13
ES2407987T3 (en) 2013-06-17
EP2153828A2 (en) 2010-02-17
HUP0302926A2 (en) 2003-12-29
EP2158905B1 (en) 2013-03-20
JP2011057705A (en) 2011-03-24
US20020119187A1 (en) 2002-08-29
EP2153827A3 (en) 2010-03-10
EP2158904A2 (en) 2010-03-03
JP6437908B2 (en) 2018-12-12
CN1466452A (en) 2004-01-07
EP2158904A3 (en) 2010-03-10
PL360708A1 (en) 2004-09-20
MXPA03002548A (en) 2003-10-14
AU1531502A (en) 2002-04-08
EP2153828B1 (en) 2017-01-18

Similar Documents

Publication Publication Date Title
WO2002026217A3 (en) Composition for the transdermal delivery of fentanyl
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
AU2001263229A1 (en) Compositions and methods for administration of pharmacologically active compounds
CA2012875A1 (en) Skin permeation enhancer compositions
WO2001032596A8 (en) Phenoxy carboxylic acid compounds and compositions for delivering active agents
WO2001035942A3 (en) Analgesic compositions containing buprenorphine
WO2002094254A3 (en) Abuse resistant pharmaceutical composition containing capsaicin
AU2001260414A1 (en) Pharmaceutical compositions for transdermal administration of anti-inflammatory agents
WO2001090091A8 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
HUP0201011A3 (en) Aminopyrimidines as sorbitol dehydrogenase inhibitors and pharmaceutical compositions containing them
GB9800526D0 (en) Organic compounds
CY1112517T1 (en) PHARMACEUTICAL FORMS MODIFIED RELEASE OF A TRULADIST
WO1995001167A3 (en) Incorporating poly-n-vinyl amide in a transdermal system
EP1695708A3 (en) Pharmaceutical composition
DE60315796D1 (en) HYDROXYNAPHTHYRIDINONCARBOXYL ACID AMIDES SUFFICIENT AS INHIBITORS OF THE HIV INTEGRASE
BG66093B1 (en) Controlled release compositions comprising nimesulide
WO2006060711A3 (en) Pharmaceutical formulation of carboxamide hiv integrase inhibitors containing a release rate controlling composition
CA2360220A1 (en) Oxadiazole compounds and compositions for delivering active agents
ZA200109862B (en) Amorphous nitric esters and their pharmaceutical compositions.
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
IS2789B (en) Medicinal preparations containing monoamine oxidase B inhibitors
WO2002034716A3 (en) Pyrrolidine modulators of ccr5 chemokine receptor activity
MY131488A (en) Low dose liquid entecavir formulations and use
WO2005060540A3 (en) Norethindrone sustained release transdermal formulation
EP1133979A3 (en) Use of specific fatty compounds for modifying the physico-chemical properties of the skin and/or the mucous membrane as agents for preventing or reducing the adhesion of micro-organisms thereon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 154857

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 524767

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002548

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2423836

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2003-890

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002530047

Country of ref document: JP

Ref document number: 1020037004485

Country of ref document: KR

Ref document number: 018164722

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001983925

Country of ref document: EP

Ref document number: 2002215315

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1020037004485

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001983925

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-890

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 524767

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 524767

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 2002215315

Country of ref document: AU